|
SNP genotypes
|
Lung function indexes
|
|---|
| |
FEV1(mean +/-s.d.)
|
FVC (mean+/-s.d.)
|
|---|
|
n
|
98
|
98
|
|
IL13-c.144 G/A
|
GG
|
98.42 + -13.95
|
96.33 + -11.88
|
| |
GA
|
93.44 + -16.58
|
92.15 + -14.79
|
| |
AA
|
92.50 + -7.78
|
89.50 + -12.02
|
|
IL4-590 C/T
|
CC
|
99.92 + -14.28
|
96.87 + -11.28
|
| |
CT
|
91.69 + -14.41
|
92.13 + -14.79
|
| |
TT
|
90.00 + -12.00
|
87.67 + 16.04
|
|
F p-value
|
0.024
| |
|
Dominant model CT/TT vs CC
|
0.006
| |
|
IL4-RP2 253/183
|
253253
|
99.75 + -14.15
|
97.07 + -11.34
|
| |
183253
|
90.59 + -14.52
|
90.74 + -14.89
|
| |
183183
|
90.00 + -12.00
|
87.67 + -16.04
|
|
F p-value
|
0.015
| |
|
Dominant model 183253/183183 vs 253253
|
0.004
| |
|
ADRB2-c.16 A/G
|
AA
|
95.16 + -19.79
|
91.74 + -16.20
|
| |
AG
|
95.91 + -12.83
|
94.91 + -11.95
|
| |
GG
|
99.47 + -13.94
|
97.19 + -11.62
|
|
ADAM33-V4 C/G
|
GG
|
99.00 + -0 c
|
98.00 + -0c
|
| |
CG
|
94.65 + -15.66
|
94.26 + -10.19
|
| |
CC
|
97.61 + -14.53
|
95.24 + -13.61
|
|
ADAM33-S1c.710 G/A
|
GG
|
97.13 + -14.81
|
95.22 + -13.05
|
| |
GA
|
94.29 + -13.96
|
92.71 + -8.92
|
| |
AA
|
-
|
-
|
|
GSDML-236 C/T
|
CC
|
99.13 + -13.20
|
94.25 + -12.07
|
| |
CT
|
96.30 + -17.48
|
94.13 + -14.34
|
| |
TT
|
96.75 + -11.34
|
96.56 + -11.04
|
|
STAT6-21 C/T
|
CC
|
97.34 + -15.74
|
95.00 + -14.28
|
| |
CT
|
96.49 + -13.52
|
94.24 + -11.73
|
| |
TT
|
96.92 + -15.73
|
97.69 + -11.01
|
- c n = 1.
- A Shapiro-Wilkoxon test showed that FEV1 is normally distributed (p > 0.05) while FVC is not (p = 0.008). Thus, ANOVA was used for FEV1 analysis while a Kruskal-Wallis test was used for FVC.
